[go: up one dir, main page]

SG11201909606RA - Probiotic molecules for reducing pathogen virulence - Google Patents

Probiotic molecules for reducing pathogen virulence

Info

Publication number
SG11201909606RA
SG11201909606RA SG11201909606RA SG11201909606RA SG 11201909606R A SG11201909606R A SG 11201909606RA SG 11201909606R A SG11201909606R A SG 11201909606RA SG 11201909606R A SG11201909606R A SG 11201909606RA
Authority
SG
Singapore
Prior art keywords
international
ontario
pct
publication
peptides
Prior art date
Application number
Inventor
Monica Angela Cella
Sarah M Curtis
Jonathon Patrick Roepke
Original Assignee
Microsintesis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microsintesis Inc filed Critical Microsintesis Inc
Publication of SG11201909606RA publication Critical patent/SG11201909606RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/195—Proteins from microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)

Abstract

ologicalRep 100.00 90.00 80.00 70.00 60.00 50.00 40.00 30.00 20.00 10.00 0.00 LDH In hi bit ion ( %) *0—Biological Rep 1 0 5 10 15 Concentration of Cell free supernatant (mg/mL) (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) REVISED VERSION (19) World Intellectual Property Organization International Bureau (43) International Publication Date 1111111111110110101011111011010 I IONN El INOUE 11101111 (10) International Publication Number WO 2018/165765 A9 20 September 2018 (20.09.2018) Wi PO I PCT (51) International Patent Classification: A61K 38/16 (2006.01) A61L 31/16 (2006.01) A23L 33/135 (2016.01) A61P 17/02 (2006.01) A23L 33/195 (2016.01) A61P 31/00 (2006.01) A61K 35/741 (2015.01) CO7K 14/195 (2006.01) A61K 35/744 (2015.01) C07K 14/315 (2006.01) A61K 35/745 (2015.01) C07K 14/335 (2006.01) A61K 35/747 (2015.01) C07K 5/10 (2006.01) A61L 15/44 (2006.01) C07K 7/06 (2006.01) A61L 27/54 (2006.01) Cl 2N 1/20 (2006.01) A61L 29/16 (2006.01) (21) International Application Number: PCT/CA2018/050320 (22) International Filing Date: 16 March 2018 (16.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/472,061 16 March 2017 (16.03.2017) US (71) Applicant: MICROSINTESIS INC. [CA/CA]; 329 Sum- mer Avenue, Oakville, Ontario L6J 1S7 (CA). (72) Inventors: CELLA, Monica Angela; 39 Ducks Landing, Apt. 302, Stratford, Prince Edward Island C1B 2X8 (CA). CURTIS, Sarah M.; 130 Balsam Road, P.O. Box 1065, Atikokan, Ontario POT 1C0 (CA). ROEPKE, Jonathon Patrick; 245 Queen Street, Apt. 3, Charlottetown, Prince Edward Island CIA 4B9 (CA). (74) Agent: LOWTHERS, Erica E. et al.; Aird & McBurney LP, Brookfield Place, 181 Bay Street, Suite 1800, Toronto, Ontario M5J 2T9 (CA). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: PROBIOTIC MOLECULES FOR REDUCING PATHOGEN VIRULENCE Figure 1 (57) : Provided are peptides that are derived from probiotic bacteria that have use for preventing and/or treating non-enteric infections in a subject. The peptides derived from the probiotic bacteria also have use for reducing the virulence of non-enteric infections in a subject. Also provided are compositions of the peptides formulated as or within food products, beverages, nutritional supplements, medicaments and the like. O [Continued on next page] WO 2018/165765 A9 IMEDIMOM0101011MENOMMIDEMHINOMEMO# TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE (88) Date of publication of the revised international search report: 22 November 2018 (22.11.2018) (15) Information about Correction: see Notice of 22 November 2018 (22.11.2018)
SG11201909606R 2017-03-16 2018-03-16 Probiotic molecules for reducing pathogen virulence SG11201909606RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472061P 2017-03-16 2017-03-16
PCT/CA2018/050320 WO2018165765A1 (en) 2017-03-16 2018-03-16 Propiotic molecules for reducing pathogen virulence

Publications (1)

Publication Number Publication Date
SG11201909606RA true SG11201909606RA (en) 2019-11-28

Family

ID=63521745

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909606R SG11201909606RA (en) 2017-03-16 2018-03-16 Probiotic molecules for reducing pathogen virulence

Country Status (16)

Country Link
US (3) US11912788B2 (en)
EP (1) EP3595698A4 (en)
JP (2) JP2020510096A (en)
KR (2) KR20190140443A (en)
CN (1) CN110621332A (en)
AU (2) AU2018233183A1 (en)
BR (1) BR112019019256A2 (en)
CA (1) CA3056719A1 (en)
CL (1) CL2019002640A1 (en)
EA (1) EA201992176A1 (en)
MA (1) MA51873A (en)
MX (1) MX2019011058A (en)
PE (1) PE20191783A1 (en)
PH (1) PH12019502340A1 (en)
SG (1) SG11201909606RA (en)
WO (1) WO2018165765A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909606RA (en) 2017-03-16 2019-11-28 Microsintesis Inc Probiotic molecules for reducing pathogen virulence
JP7252145B2 (en) * 2017-03-16 2023-04-04 マイクロシンテシス インコーポレイテッド Compositions and methods comprising probiotic molecules
BR112022000041A2 (en) * 2019-07-02 2022-03-15 Microsintesis Inc Quorum detection inhibitors and/or postbiotic metabolites and related methods
CN115039884B (en) * 2021-05-14 2023-11-03 江苏艾兰得营养品有限公司 Lactobacillus rhamnosus with function of inhibiting growth of Proteus mirabilis, and probiotic composition, fermentation liquor and application thereof
CA3150903C (en) 2021-05-14 2025-05-27 Ivc Nutrition Corporation Probiotic for inhibiting growth of proteus mirabilis, and fermentation broth and application thereof
KR102337951B1 (en) * 2021-06-25 2021-12-13 주식회사 비피도 Lactobacillus helveticus GUT10 for improvement, prevention or treatment of urinary tract infection and composition comprising the same
KR102356423B1 (en) * 2021-07-02 2022-02-09 (주)에스디생명공학 Composition Comprising Complex Strain with Anti-microbial, Skin Moisturizing, Anti-atopy, Skin Barrier, and Anti-wrinkle Property as Active Ingredient
KR102618322B1 (en) * 2021-10-08 2023-12-27 순천향대학교 산학협력단 Novel Lactobacillus strain and composition for preventing, treating, or improving tuberculosis comprising the same
CN114106096A (en) * 2021-11-16 2022-03-01 华南理工大学 Hexapeptide with sleep improving activity and application thereof
CN114591879B (en) * 2022-05-11 2022-12-06 中国农业大学 A kind of lactobacillus fermentum and application thereof for inhibiting Helicobacter pylori
KR102551065B1 (en) * 2022-05-12 2023-07-03 중앙대학교 산학협력단 Composition Comprising LAB Derived from Kimchi for Preventing Formation of Biofilm
CN116478882A (en) * 2023-05-05 2023-07-25 石河子大学 Preparation method of acid-producing mixed bacteria preparation capable of improving daily weight gain and feed conversion rate of sheep
CN119242516A (en) * 2024-10-31 2025-01-03 广西民族大学 A strain of Bacillus faecalis GXUN3754 and its application in controlling root-knot nematodes of elephant-ear bean

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0395309B1 (en) 1989-04-28 1995-12-27 Takara Shuzo Co. Ltd. Human calpastatin-like polypeptide
FR2686085B1 (en) 1992-01-10 1995-08-04 Agronomique Inst Nat Rech PEPTIDES REPRESENTING FRAGMENTS OF CMP, ANTIBODIES DIRECTED AGAINST SUCH PEPTIDES, AND THEIR USES.
WO1994018832A1 (en) 1993-02-26 1994-09-01 Dana-Farber Cancer Institute, Inc. Cd4 mediated modulation of lipid kinases
US7393663B2 (en) 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
JP4476934B2 (en) 2003-04-14 2010-06-09 明治乳業株式会社 Novel peptide and immunostimulant, functional food and method for producing functional food
DE10317870A1 (en) * 2003-04-17 2004-11-04 Crompton Vinyl Additives Gmbh New stabilizer system for stabilizing halogen-containing polymers
AU2004315890A1 (en) * 2003-12-04 2005-09-01 Burwell, Steve Mr. Methods and compositions for preventing biofilm formations, reducing existing biofilms, and for reducing existing biofilms, and for reducing populations of bacteria
US7306677B2 (en) * 2004-01-30 2007-12-11 Boston Scientific Corporation Clamping fixture for coating stents, system using the fixture, and method of using the fixture
JP5068174B2 (en) 2004-12-23 2012-11-07 カンピナ ネーデルランド ホールディング ビー．ブイ． Protein hydrolyzate concentrated in peptides inhibiting DPP-IV and uses thereof
JP2009516738A (en) * 2005-11-21 2009-04-23 ティーガスク−ザ アグリカルチャー アンド フード デベロップメント オーソリティー Casein-derived antimicrobial peptide and Lactobacillus strain producing the same
US8431528B2 (en) 2008-05-16 2013-04-30 University Of Maryland, Baltimore Antibacterial Lactobacillus GG peptides and methods of use
EP4019529A1 (en) * 2008-06-27 2022-06-29 MicroSintesis Inc. Probiotic bacterial molecules and their use in methods to treat/prevent infection by harmful bacteria and to provide nutritional health
EP2550529B1 (en) 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
PT105073A (en) 2010-04-26 2011-10-26 Consejo Superior Investigacion PROCESS OF OBTAINING BIOACTIVE PEPTIDIC EXTRACTS THROUGH HYDROLYSIS OF MILK SERUM PROTEINS WITH CYNARA CARDUNCULUS ENZYMES, REFERRING EXTRACTS AND THEIR USES
WO2014020209A1 (en) 2012-07-30 2014-02-06 Consejo Superior De Investigaciones Científicas (Csic) Use of milk protein hydrolysates as gastrointestinal protectors
WO2014035345A1 (en) * 2012-08-29 2014-03-06 Agency For Science, Technology And Research Peptides and uses thereof
EP2890706A1 (en) 2012-08-31 2015-07-08 Westfälische Wilhelms-Universität Münster Methods and peptides for preventing and treating a bcr-abl and a c-abl associated disease
US9861666B2 (en) * 2013-08-12 2018-01-09 Mansel Griffiths Antiviral methods and compositions comprising probiotic bacterial molecules
SG10201803535RA (en) 2013-10-31 2018-05-30 Hutchison Biofilm Medical Solutions Ltd Use of peptides in antibiotic resistance
WO2016172722A1 (en) 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
SG11201909606RA (en) 2017-03-16 2019-11-28 Microsintesis Inc Probiotic molecules for reducing pathogen virulence
JP7252145B2 (en) 2017-03-16 2023-04-04 マイクロシンテシス インコーポレイテッド Compositions and methods comprising probiotic molecules

Also Published As

Publication number Publication date
WO2018165765A9 (en) 2018-11-22
WO2018165765A1 (en) 2018-09-20
JP2023036938A (en) 2023-03-14
CN110621332A (en) 2019-12-27
BR112019019256A2 (en) 2020-04-14
EP3595698A4 (en) 2020-12-23
EA201992176A1 (en) 2020-03-04
PH12019502340A1 (en) 2020-10-19
MA51873A (en) 2020-01-22
CL2019002640A1 (en) 2020-05-15
PE20191783A1 (en) 2019-12-24
US11912788B2 (en) 2024-02-27
CA3056719A1 (en) 2018-09-20
MX2019011058A (en) 2019-12-09
US20250313595A1 (en) 2025-10-09
AU2018233183A1 (en) 2019-10-31
US20240150399A1 (en) 2024-05-09
AU2022203650B2 (en) 2024-04-11
EP3595698A1 (en) 2020-01-22
JP2020510096A (en) 2020-04-02
AU2022203650A1 (en) 2022-06-16
KR20190140443A (en) 2019-12-19
KR20240046640A (en) 2024-04-09
US20200017547A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
SG11201909606RA (en) Probiotic molecules for reducing pathogen virulence
SG11201909602TA (en) Compositions and methods involving probiotic molecules
SG11201811432WA (en) Rna for cancer therapy
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201906161VA (en) Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201909949XA (en) Targeted immunotolerance
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201907420VA (en) Inhibition of smarca2 for treatment of cancer
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201804770QA (en) Method and arrangement for recovery of salt
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201907196YA (en) Composition and methods for preventing radiation injury and promoting tissue regeneration
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201908393YA (en) Modulators of pcsk9 expression
SG11201809594WA (en) Nicotine particles and compositions
SG11201810940XA (en) Methods of treating pancreatic cancer
SG11201805001UA (en) Method of treating influenza a
SG11201909825VA (en) Hsp90 inhibitor oral formulations and related methods
SG11201909837YA (en) Methods for treating lung disorders